Your Rare Disease CRO

Delivering high-quality, accelerated, and cost controlled clinical trial services through a partnership model.

Rare Disease CRO

Rare & Genetic Disease CRO.

Navigating your Rare & Genetic Disease Clinical Trial.

Venturing into the world of rare and genetic diseases is a journey filled with promise and potential. While these unique conditions present distinct challenges, they also open doors to groundbreaking discoveries.

As a specialized CRO, we embrace every stage of this voyage with enthusiasm and expertise. Instead of seeing hurdles, we see opportunities for innovation.

Our partnership model is our strength; by joining forces with sponsors and experts, we amplify our collective knowledge and resources. This unity propels us forward, enabling us to pave optimistic pathways towards effective therapies.

Together, we're not just navigating the landscape; we're shaping a brighter future for those touched by these conditions.


The Celero Way

A pathway to high-quality, cost-controlled, accelerated trials tailored to your needs.

Celero’s accelerated controlled pathway and timelines

Our Process: Q&A

At Celero, we prioritize rigorous adherence to established Standard Operating Procedures (SOPs) to guarantee top-tier quality in our clinical trials. Our dedicated teams are continually trained on both trial protocols and Good Clinical Practice (GCP), ensuring a consistent level of expertise across the board.


We emphasize regular site monitoring to validate data accuracy and uphold patient safety, supplemented by periodic independent audits that ensure consistent compliance and protocol adherence. Our adoption of validated electronic data capture systems is a testament to our commitment to unparalleled data integrity.


Our proactive risk management strategies, coupled with our transparent communication lines with stakeholders, mean that potential challenges are addressed promptly and efficiently. By placing unwavering emphasis on participant safety, maintaining meticulous records, strictly adhering to regulatory guidelines, and integrating constructive feedback mechanisms, we strive to consistently raise the bar for the quality and integrity of clinical trials.

Our startup & recruitment timelines are significantly shorter due to:  

  • Relationship and Experience with Regulators: We understand their expectations for submission contents. 
  • Strategic Country Selection: We opt for countries with commercial opportunities and unmet needs. This not only provides accelerated startup phases but also faster recruitment due to large populations in emerging markets and high prevalence of specific diseases,  in addition to accelerated registration in some cases. 
  • Recruitment Efficiency: Our access to large populations in emerging markets, combined with our global reach for multi-centric trials and collaboration with experienced Principal Investigators (PIs) in specific disease areas, expedites our recruitment process. 

Additionally, we have access to patient databases through our sites and PIs, ensuring a smoother recruitment phase. 

A cost-controlled agreement is our promise to efficiently manage the costs associated with your clinical trial, keeping them within the agreed budget. This offers a fixed clinical trial budget that is both predictable and controlled. This allows you to trust our services, knowing that unexpected costs and change orders are unlikely. At Celero we demonstrate financial responsibility, fostering a transparent and trusting relationship with our sponsors. 

We understand that every biotech company has unique needs. Our approach is tailored to your requirements, ensuring that every phase of the clinical trial, from startup to recruitment and final reporting, aligns with your specific objectives, outcomes, budget, and timelines. 

We do not only perform a scientific experiment (Clinical trial); At Celero we strategically select countries with high commercial and growth opportunities by addressing their unmet  needs. These strategies allow our sponsors to achieve accelerated registrations and high market share providing you with an optimal return on your clinical trial investment. 

Our partnership model signifies a collaborative approach. We don't see ourselves as just another vendor; we act as an extension of your clinical, registration and commercial team. This symbiotic relationship ensures that your objectives become our milestones, driving both parties towards shared success. 


Rare & Genetic Disease Enablers.

We provide an end-to-end commercially driven solution with global access to top industry experts, influential key opinion leaders (KOLs), regulatory authorities, premier clinical trial sites, and diverse patient access opportunities.

At Celero, we prioritize rigorous adherence to established Standard Operating Procedures (SOPs) to guarantee top-tier quality in our clinical trials. Our dedicated teams are continually trained on both trial protocols and Good Clinical Practice (GCP), ensuring a consistent level of expertise across the board.


We emphasize regular site monitoring to validate data accuracy and uphold patient safety, supplemented by periodic independent audits that ensure consistent compliance and protocol adherence. Our adoption of validated electronic data capture systems is a testament to our commitment to unparalleled data integrity.


Our proactive risk management strategies, coupled with our transparent communication lines with stakeholders, mean that potential challenges are addressed promptly and efficiently. By placing unwavering emphasis on participant safety, maintaining meticulous records, strictly adhering to regulatory guidelines, and integrating constructive feedback mechanisms, we strive to consistently raise the bar for the quality and integrity of clinical trials.

Our startup & recruitment timelines are significantly shorter due to:  

  • Relationship and Experience with Regulators: We understand their expectations for submission contents. 
  • Strategic Country Selection: We opt for countries with commercial opportunities and unmet needs. This not only provides accelerated startup phases but also faster recruitment due to large populations in emerging markets and high prevalence of specific diseases,  in addition to accelerated registration in some cases. 
  • Recruitment Efficiency: Our access to large populations in emerging markets, combined with our global reach for multi-centric trials and collaboration with experienced Principal Investigators (PIs) in specific disease areas, expedites our recruitment process. 

Additionally, we have access to patient databases through our sites and PIs, ensuring a smoother recruitment phase. 

A cost-controlled agreement is our promise to efficiently manage the costs associated with your clinical trial, keeping them within the agreed budget. This offers a fixed clinical trial budget that is both predictable and controlled. This allows you to trust our services, knowing that unexpected costs and change orders are unlikely. At Celero we demonstrate financial responsibility, fostering a transparent and trusting relationship with our sponsors. 

We understand that every biotech company has unique needs. Our approach is tailored to your requirements, ensuring that every phase of the clinical trial, from startup to recruitment and final reporting, aligns with your specific objectives, outcomes, budget, and timelines. 

We do not only perform a scientific experiment (Clinical trial); At Celero we strategically select countries with high commercial and growth opportunities by addressing their unmet  needs. These strategies allow our sponsors to achieve accelerated registrations and high market share providing you with an optimal return on your clinical trial investment. 

Our partnership model signifies a collaborative approach. We don't see ourselves as just another vendor; we act as an extension of your clinical, registration and commercial team. This symbiotic relationship ensures that your objectives become our milestones, driving both parties towards shared success. 

Celero enabler, global industry experts

Global Rare & Genetic Disease Industry Experts

The executive team at Celero has expertise from overseeing 80 trials spanning various clinical development stages (P1-P4), conducted in over 25 countries, including APAC, LATAM, MEA, Eurasia, EU, and Central & Eastern Europe.

Celero enabler, key opinion leaders, regulators and sites

Rare & Genetic Disease Key Opinion Leaders, Regulators and Sites

Celero has built strong relationships with significant figures in clinical research, collaborating closely with diverse trial sites and key opinion leaders (KOLs) to ensure our trials are innovative, ethically conducted, and in compliance with global regulatory guidelines.

Celero enabler, naive diverse high prevalence patients

Naive, Diverse and High Prevalence Rare & Genetic Disease Patients

We connect sponsors with treatment-naïve patients for controlled therapeutic evaluations, target populations with high disease prevalence for focused studies, and engage with clinically diverse groups to mirror real-world research complexities.

Celero global industry experts

Our Vision
Healing humanity one Biotech at a time

Celero Rare & Genetic Disease Expert

Heba M, Rare & Genetic Disease Expert

Learn how we can assist in driving your Rare & Genetic Disease research forward.

Contact Us

Speak to an Expert

Share by: